Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Paychex, Inc. (PAYX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Paychex, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Paychex, Inc. trades at $108.43 (market cap $38.25B). The key difference: Alnylam Pharmaceuticals, Inc. and Paychex, Inc. are close in size by market cap, and Paychex, Inc. pays a 4.43% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PAYX | |
|---|---|---|
Market Cap | $39.89B | $38.25B |
Sector | Health | Industrials |
52-Week High | $491.22 | $147.99 |
52-Week Low | $278.09 | $85.57 |
Enterprise Value | $38.15B | $41.73B |
Dividend Yield | — | 4.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Paychex (PAYX) trades at $107.54, up 1.16% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with 27.03% net margin and 44.77% ROE, though valuation ratios like P/E of 22 and P/S of 5.95 are elevated. Recent Q1 2026 EPS of $1.32 beat expectations, and the company maintains dividend payments with a $1.19 distribution scheduled for May 29, 2026. Cash flow from operations remains robust at $1.90B for 2025.
Outlook is cautiously optimistic with a consensus price target of $110.00, though analyst ratings are mixed (63.33% Hold). Key risks include macroeconomic sensitivity to small business hiring and integration challenges from acquisitions. The stock's current price near resistance at $110 suggests limited near-term upside without significant catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
